CG Oncology's cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 PIVOT-006
What's the news? CG Oncology (NASDAQ: CGON) reported positive topline results from PIVOT-006, its Phase 3 registrational trial of cretostimogene grenadenorepvec (an investigational oncolytic immunotherapy delivered directly into the bladder) as an adjuvant treatment — given alongside standard care — in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC) following complete tumour resection. The trial met its primary endpoint: cretostimogene reduced the risk of cancer recurrence by 68% versus the surveillance control arm, with a hazard ratio of 0.32 (95% CI 0.23–0.45; p<0.0001) at a median follow-up of 17 months (data cut-off 26 October 2026).
Why it matters: There are currently no US FDA-approved adjuvant treatment options for this population of roughly 50,000 patients, so a positive pivotal readout here opens a much broader potential patient base for cretostimogene beyond the earlier BCG-unresponsive setting. The drug was generally well tolerated: no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations. PIVOT-006 enrolled 367 patients at around 90 sites in the US and Canada, comparing adjuvant intravesical cretostimogene against surveillance after complete tumour resection.
Next steps: PIVOT-006 data will be presented as a late-breaking podium presentation at the Society of Urologic Oncology Annual Meeting on 2 December 2026 and will support a second Biologics License Application (BLA) in intermediate-risk and high-grade Ta NMIBC, anticipated in Q2 2027. Based on FDA feedback, the company is broadening its first BLA in BCG-unresponsive NMIBC — previously focused on patients with carcinoma in situ with or without papillary tumours — to also include high-grade papillary-only disease, with submission now expected by the end of March 2027. Cretostimogene has previously received FDA Fast Track and Breakthrough Therapy designations for BCG-unresponsive NMIBC, and its development programme covers more than 700 patients with NMIBC.
Read more: GlobeNewswire, 16 November 2026